What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
His primary areas of study are Immunology, Internal medicine, Pathology, Cancer research and Gastroenterology.
His Internal medicine study integrates concerns from other disciplines, such as Surgery and Oncology.
His biological study spans a wide range of topics, including Cancer, Colorectal cancer, Intestinal mucosa and In vivo.
His Cancer research research is multidisciplinary, incorporating perspectives in Cell growth, Cancer cell, Interleukin 6, Apoptosis and Signal transduction.
His Gastroenterology study combines topics from a wide range of disciplines, such as Clinical endpoint, Prospective cohort study, Phases of clinical research and Adenocarcinoma.
The study incorporates disciplines such as Proinflammatory cytokine, Molecular biology and Immune system in addition to Cytokine.
His most cited work include:
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. (1072 citations)
- p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias (682 citations)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Immunology, Hepatocellular carcinoma and Cancer research.
His research integrates issues of Surgery and Oncology in his study of Internal medicine.
His study connects Liver transplantation and Gastroenterology.
Many of his studies on Immunology apply to Virology as well.
His Hepatocellular carcinoma study incorporates themes from Carcinoma and Ramucirumab.
Peter R. Galle focuses mostly in the field of Cancer research, narrowing it down to matters related to Cancer and, in some cases, Pathology.
He most often published in these fields:
- Internal medicine (40.17%)
- Gastroenterology (20.08%)
- Immunology (17.70%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (40.17%)
- Gastroenterology (20.08%)
- Hepatocellular carcinoma (15.42%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Gastroenterology, Hepatocellular carcinoma, In patient and Oncology are his primary areas of study.
His study in Ramucirumab, Cirrhosis, Cohort, Fatty liver and Liver disease falls within the category of Internal medicine.
His Gastroenterology research incorporates themes from Fibrosis, Prospective cohort study, Liver transplantation and Disease.
His Hepatocellular carcinoma research is multidisciplinary, relying on both Carcinoma, Proportional hazards model and First line treatment.
He interconnects Bevacizumab, Open label, Atezolizumab and Biomarker in the investigation of issues within Oncology.
The concepts of his Sorafenib study are interwoven with issues in Clinical trial, Progression-free survival and Systemic therapy.
Between 2018 and 2021, his most popular works were:
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
- IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) (97 citations)
- Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. (51 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
His main research concerns Internal medicine, Hepatocellular carcinoma, In patient, Gastroenterology and Oncology.
His research links Resection with Internal medicine.
The Hepatocellular carcinoma study combines topics in areas such as Bevacizumab, Carcinoma and First line treatment.
His work in Gastroenterology addresses subjects such as Ramucirumab, which are connected to disciplines such as Hazard ratio, Safety profile and Elevated alpha-fetoprotein.
His Oncology research is multidisciplinary, incorporating elements of Open label, Scoring system, Neuroblastoma RAS viral oncogene homolog, Biomarker and Primary tumor.
His Pathology research includes themes of Liver injury and Liver function tests.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
